* Eledon Pharmaceuticals Inc ELDN.OQ ELDN.O is expected
to show no change in quarterly revenue when it reports
results on August 9 (estimated).
*
* Refinitiv's mean analyst estimate for Eledon
Pharmaceuticals
Inc is for a loss of 46 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Eledon
Pharmaceuticals Inc is $12, above its last closing price
of $1.29.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Mar. 31 2023 -0.58 -0.60 -0.75 Missed -25.2
Dec. 31 2023 -0.78 -0.70 -0.69 Beat 1.6
Sep. 30 2022 -0.68 -0.68 -0.73 Missed -7.4
Jun. 30 2022 -0.70 -0.70 -0.65 Beat 7.7
Mar. -0.67 -0.68 -0.69 Missed -1.8
31 2022
Dec. 31 2021 -0.75 -0.59 Beat 21.3
Sep. 30 2021 -0.63 -0.65 -0.66 Missed -2.2
Jun. 30 2021 -0.58 -0.57 -0.50 Beat 11.9
This summary was machine generated August 7 at 12:26 GMT. All
figures in US dollars unless otherwise stated